Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

Autor: Romera, Alvaro, Peredpaya, Sergiy, Shparyk, Yaroslav, Bondarenko, Igor, Mendonça Bariani, Giovanni, Abdalla, Kathia Cristina, Roca, Enrique, Franke, Fábio, Melo Cruz, Felipe, Ramesh, Anita, Ostwal, Vikas, Shah, Pradeep, Rahuman, Sajeed Abdul, Paravisini, Alexandra, Huerga, Camino, Del Campo García, Ana, Millán, Susana
Zdroj: In The Lancet Gastroenterology & Hepatology December 2018 3(12):845-855
Databáze: ScienceDirect